Adiponectin, C1Q and Collagen Domain Containing (ADIPOQ) (AA 55-69), (N-Term) antibody

Details for Product No. ABIN965514
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

 
Antigen
Synonyms ACDC, ACRP30, ADIPQTL1, ADPN, APM-1, APM1, GBP28, APN, Acdc, apM1, 30kDa, adipo, Acrp30, ADN, MGC84292, ADIPOQ
Epitope
AA 55-69, N-Term
(19), (17), (8), (3), (3), (3), (3), (2), (2), (2), (2), (2), (2), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1)
Reactivity
Human, Mouse (Murine)
(252), (96), (74), (20), (16), (16), (15), (4), (4)
Host
Rabbit
(181), (122), (8), (7), (4), (1)
Clonality
Polyclonal
Conjugate
Un-conjugated
(30), (9), (4), (1), (1), (1), (1), (1), (1), (1), (1)
Application
Immunohistochemistry (IHC)
(239), (195), (42), (35), (31), (26), (25), (14), (13), (10), (8), (7), (4), (4), (4), (4), (3), (1), (1), (1)
Pubmed 6 references available
Catalog no. ABIN965514
Quantity 0.1 mg
Price
316.25 $   Plus shipping costs $45.00
Options
Shipping to United States (Change)
Availability Will be delivered in 5 to 7 Business Days

Order hotline:

  • +1 404 474 4654
  • +1 888 205 9894 (TF)
Immunogen Polyclonal antibody produced in rabbits immunizing with a synthetic peptide corresponding to residues 55-69 of human ADIPOQ(Adiponectin precursor)
Purification Purified by antigen-specific affinity chromatography.
Alternative Name ADIPOQ
Background ADIPOQ (Adiponectin) is an important negative regulator in hematopoiesis and immunesystems. ADIPOQ may be involved in ending inflammatory responses through its inhibitory functions. ADIPOQ inhibits endothelial NF-kappa-B signaling through a cAMP-dependent pathway. It inhibits TNF-alpha-induced expression of endothelial adhesion molecules. ADIPOQ is involved in the control of fat metabolism and insulin sensitivity. Defects in ADIPOQ are the cause of adiponectin deficiency. The result is a very low concentration of plasma adiponectin. The decreased adiponectin plasma levels are associated with obesity insulin resistance, and diabetes type 2.
Application Notes ELISA, Western blotting: 1µg/ml for 2hrs.
Restrictions For Research Use only
Format Liquid
Buffer This antibody is stored in PBS, 50% glycerol
Preservative Sodium azide
Storage -20 °C
Product cited in: Nakano, Tobe, Choi-Miura et al.: "Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma." in: Journal of biochemistry, Vol. 120, Issue 4, pp. 803-12, 1997 (PubMed).

Arita, Kihara, Ouchi et al.: "Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity." in: Biochemical and biophysical research communications, Vol. 257, Issue 1, pp. 79-83, 1999 (PubMed).

Saito, Tobe, Minoshima et al.: "Organization of the gene for gelatin-binding protein (GBP28)." in: Gene, Vol. 229, Issue 1-2, pp. 67-73, 1999 (PubMed).

Schäffler, Orsó, Palitzsch et al.: "The human apM-1, an adipocyte-specific gene linked to the family of TNF's and to genes expressed in activated T cells, is mapped to chromosome 1q21.3-q23, a susceptibility locus identified for familial combined hyperlipidaemia (FCH)." in: Biochemical and biophysical research communications, Vol. 260, Issue 2, pp. 416-25, 1999 (PubMed).

Yokota, Oritani, Takahashi et al.: "Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages." in: Blood, Vol. 96, Issue 5, pp. 1723-32, 2000 (PubMed).

Ouchi, Kihara, Arita et al.: "Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway." in: Circulation, Vol. 102, Issue 11, pp. 1296-301, 2000 (PubMed).

Hosts (181), (122), (8), (7), (4), (1)
Reactivities (252), (96), (74), (20), (16), (16), (15), (4), (4)
Applications (239), (195), (42), (35), (31), (26), (25), (14), (13), (10), (8), (7), (4), (4), (4), (4), (3), (1), (1), (1)
Conjugates (30), (9), (4), (1), (1), (1), (1), (1), (1), (1), (1)
Epitopes (19), (17), (8), (3), (3), (3), (3), (2), (2), (2), (2), (2), (2), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1)
back to top